446 related articles for article (PubMed ID: 11238516)
1. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
[TBL] [Abstract][Full Text] [Related]
2. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
Whorwood CB; Stewart PM
J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.
Li A; Tedde R; Krozowski ZS; Pala A; Li KX; Shackleton CH; Mantero F; Palermo M; Stewart PM
Am J Hum Genet; 1998 Aug; 63(2):370-9. PubMed ID: 9683587
[TBL] [Abstract][Full Text] [Related]
4. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
[TBL] [Abstract][Full Text] [Related]
5. Apparent mineralocorticoid excess: report of six new cases and extensive personal experience.
Morineau G; Sulmont V; Salomon R; Fiquet-Kempf B; Jeunemaître X; Nicod J; Ferrari P
J Am Soc Nephrol; 2006 Nov; 17(11):3176-84. PubMed ID: 17035606
[TBL] [Abstract][Full Text] [Related]
6. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
Carvajal CA; Gonzalez AA; Romero DG; González A; Mosso LM; Lagos ET; Hevia Mdel P; Rosati MP; Perez-Acle TO; Gomez-Sanchez CE; Montero JA; Fardella CE
J Clin Endocrinol Metab; 2003 Jun; 88(6):2501-7. PubMed ID: 12788846
[TBL] [Abstract][Full Text] [Related]
7. A genetic defect resulting in mild low-renin hypertension.
Wilson RC; Dave-Sharma S; Wei JQ; Obeyesekere VR; Li K; Ferrari P; Krozowski ZS; Shackleton CH; Bradlow L; Wiens T; New MI
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10200-5. PubMed ID: 9707624
[TBL] [Abstract][Full Text] [Related]
8. Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation.
Ferrari P; Krozowski Z
Kidney Int; 2000 Apr; 57(4):1374-81. PubMed ID: 10760070
[TBL] [Abstract][Full Text] [Related]
9. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
Al-Harbi T; Al-Shaikh A
J Pediatr Endocrinol Metab; 2012; 25(11-12):1083-8. PubMed ID: 23329753
[TBL] [Abstract][Full Text] [Related]
10. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
[TBL] [Abstract][Full Text] [Related]
11. Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
Nikkilä H; Tannin GM; New MI; Taylor NF; Kalaitzoglou G; Monder C; White PC
J Clin Endocrinol Metab; 1993 Sep; 77(3):687-91. PubMed ID: 8370690
[TBL] [Abstract][Full Text] [Related]
12. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state.
Li A; Li KX; Marui S; Krozowski ZS; Batista MC; Whorwood CB; Arnhold IJ; Shackleton CH; Mendonca BB; Stewart PM
J Hypertens; 1997 Dec; 15(12 Pt 1):1397-402. PubMed ID: 9431844
[TBL] [Abstract][Full Text] [Related]
13. In vitro expression studies of a novel mutation delta299 in a patient affected with apparent mineralocorticoid excess.
Lin-Su K; Zhou P; Arora N; Betensky BP; New MI; Wilson RC
J Clin Endocrinol Metab; 2004 May; 89(5):2024-7. PubMed ID: 15126515
[TBL] [Abstract][Full Text] [Related]
14. Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess.
Nunez BS; Rogerson FM; Mune T; Igarashi Y; Nakagawa Y; Phillipov G; Moudgil A; Travis LB; Palermo M; Shackleton C; White PC
Hypertension; 1999 Oct; 34(4 Pt 1):638-42. PubMed ID: 10523339
[TBL] [Abstract][Full Text] [Related]
15. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.
White PC; Mune T; Agarwal AK
Endocr Rev; 1997 Feb; 18(1):135-56. PubMed ID: 9034789
[TBL] [Abstract][Full Text] [Related]
16. Congenital deficiency of 11beta-hydroxysteroid dehydrogenase (apparent mineralocorticoid excess syndrome): diagnostic value of urinary free cortisol and cortisone.
Palermo M; Delitala G; Mantero F; Stewart PM; Shackleton CH
J Endocrinol Invest; 2001 Jan; 24(1):17-23. PubMed ID: 11227727
[TBL] [Abstract][Full Text] [Related]
17. The codon 213 of the 11beta-hydroxysteroid dehydrogenase type 2 gene is a hot spot for mutations in apparent mineralocorticoid excess.
Rogoff D; Smolenicka Z; Bergadá I; Vallejo G; Barontini M; Heinrich JJ; Ferrari P
J Clin Endocrinol Metab; 1998 Dec; 83(12):4391-3. PubMed ID: 9851783
[TBL] [Abstract][Full Text] [Related]
18. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
Pediatr Res; 1997 Jan; 41(1):25-9. PubMed ID: 8979285
[TBL] [Abstract][Full Text] [Related]
19. [Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years].
Rodríguez JA
Rev Med Chil; 2000 Jan; 128(1):17-26. PubMed ID: 10883518
[TBL] [Abstract][Full Text] [Related]
20. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene.
Stewart PM; Krozowski ZS; Gupta A; Milford DV; Howie AJ; Sheppard MC; Whorwood CB
Lancet; 1996 Jan; 347(8994):88-91. PubMed ID: 8538347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
